Description: Antiplatelet Agent, Glycoprotein IIb/IIIa Inhibitor
CSA NA – FDA Approved – REMS (N) – Can Ship
How Does It Work
Eptifibatide, Integrilin is a cyclic heptapeptide which blocks the platelet glycoprotein IIb/IIIa receptor, the binding site for fibrinogen, von Willebrand factor, and other ligands. Inhibition of binding at this final common receptor reversibly blocks platelet aggregation and prevents thrombosis.
Indications For Use
Acute Coronary Syndrome
Before starting Eptifibatide, Integrilin make sure your physician is aware of any allergies or medications you currently take. The most common complication of taking Eptifibatide, Integrilin is bleeding, including retroperitoneal, pulmonary, and spontaneous GI and/or GU bleeding; monitor closely for bleeding, especially the arterial access site for the cardiac catheterization. Acute thrombocytopenia has (immune mediated and nonimmune mediated) has occurred and may occur within 24 hours of initiation.
Intravenous: Bolus injection of 180mcg/kg (maximum: 22.6 mg), followed by a continuous infusion of 2 mcg/kg/minute (maximum: 15 mg/hour); a second bolus of 180 mcg/kg (maximum: 22.6 mg) should be administered 10 minutes after the first bolus; may continue infusion for up to 18 to 24 hours after PCI.
Pharmacist Tips On Using
How to Take:
Should be administered intravenously with a bolus push. Begin continuous infusion (using an IV infusion pump) immediately following bolus administration, administered undiluted directly from the 100 mL vial. The 100 mL vial should be spiked with a vented infusion set.
The frequency of side effects has not been recorded in all cases, but the following are the most commonly reported:
Hemorrhage, hypotension, thrombocytopenia, injection site reaction.
Frequently Asked Questions
What do I do if side effects are intolerable?
If side effects are causing a lot of distress speak to your physician as soon as possible to discuss options.